Entellus Medical Inc (NASDAQ:ENTL) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Tuesday, May 9th.
According to Zacks, “Entellus Medical, Inc. is a medical technology company. It is engaged in the designing, development and commercialization of products for the treatment of chronic sinusitis. The company operates primarily in the United States and Canada. Entellus Medical, Inc. is headquartered in Plymouth, Minnesota. “
Several other research firms have also commented on ENTL. Canaccord Genuity set a $21.00 target price on shares of Entellus Medical and gave the company a “buy” rating in a report on Monday, January 23rd. Bank of America Corp lowered shares of Entellus Medical from a “buy” rating to an “underperform” rating and set a $16.00 target price on the stock. in a report on Wednesday, February 22nd. Finally, BTIG Research lowered shares of Entellus Medical from a “buy” rating to a “neutral” rating in a report on Wednesday, February 22nd. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $21.83.
Shares of Entellus Medical (NASDAQ:ENTL) traded down 0.08% during mid-day trading on Tuesday, reaching $12.98. The company had a trading volume of 162,107 shares. Entellus Medical has a 52-week low of $11.47 and a 52-week high of $22.63. The stock’s market capitalization is $284.47 million. The company’s 50-day moving average is $13.73 and its 200 day moving average is $16.25.
Entellus Medical (NASDAQ:ENTL) last released its quarterly earnings results on Wednesday, May 3rd. The medical technology company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.04. Entellus Medical had a negative net margin of 36.91% and a negative return on equity of 53.20%. The business had revenue of $19.11 million for the quarter, compared to analyst estimates of $19.61 million. During the same period last year, the firm earned ($0.37) earnings per share. Entellus Medical’s revenue for the quarter was up 13.0% compared to the same quarter last year. Analysts anticipate that Entellus Medical will post ($1.36) EPS for the current fiscal year.
WARNING: This piece was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2017/05/19/entellus-medical-inc-entl-downgraded-by-zacks-investment-research-updated.html.
In other news, CFO Brent Moen purchased 6,100 shares of the stock in a transaction on Monday, May 8th. The stock was purchased at an average price of $12.21 per share, for a total transaction of $74,481.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Robert S. White purchased 10,000 shares of the stock in a transaction on Monday, May 8th. The shares were purchased at an average price of $12.24 per share, with a total value of $122,400.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 17,700 shares of company stock worth $216,625. 9.10% of the stock is owned by corporate insiders.
Several hedge funds have recently added to or reduced their stakes in ENTL. Discovery Group I LLC raised its stake in Entellus Medical by 6.5% in the fourth quarter. Discovery Group I LLC now owns 745,983 shares of the medical technology company’s stock valued at $14,151,000 after buying an additional 45,698 shares in the last quarter. Frontier Capital Management Co. LLC bought a new stake in Entellus Medical during the first quarter valued at $6,464,000. Kingdon Capital Management L.L.C. raised its stake in Entellus Medical by 79.6% in the first quarter. Kingdon Capital Management L.L.C. now owns 450,371 shares of the medical technology company’s stock valued at $6,215,000 after buying an additional 199,615 shares in the last quarter. Vanguard Group Inc. raised its stake in Entellus Medical by 77.8% in the first quarter. Vanguard Group Inc. now owns 424,823 shares of the medical technology company’s stock valued at $5,862,000 after buying an additional 185,833 shares in the last quarter. Finally, Cortina Asset Management LLC raised its stake in Entellus Medical by 22.6% in the first quarter. Cortina Asset Management LLC now owns 412,323 shares of the medical technology company’s stock valued at $5,690,000 after buying an additional 75,879 shares in the last quarter. Institutional investors own 60.67% of the company’s stock.
About Entellus Medical
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Entellus Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc and related companies with MarketBeat.com's FREE daily email newsletter.